Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Adynovi

    - PMLiVE

    Sobi receives NICE recommendation for Altuvoct in severe haemophilia A

    Approximately 7,700 people in England are living with the genetic bleeding disorder

    - PMLiVE

    Sobi receives MHRA approval for Altuvoct in severe or moderate haemophilia A

    The factor VIII replacement therapy has been authorised to treat and prevent bleeding in children and adults

    - PMLiVE

    Novo Nordisk’s haemophilia A therapy Mim8 shows promise in late-stage study

    The inherited bleeding disorder accounts for up to 85% of the 1,125,000 global haemophilia cases

    - PMLiVE

    Pfizer shares positive late-stage results for haemophilia A gene therapy

    The rare bleeding disorder occurs in approximately 25 in every 100,000 male births globally

    - PMLiVE

    Sanofi/Sobi’s haemophilia A therapy shows ‘highly effective’ bleed protection in children

    The rare bleeding disorder affects approximately one in every 5,000 male births annually

    - PMLiVE

    Novo Nordisk shares positive results for Mim8 in late-stage haemophilia A trial

    The inherited bleeding disorder accounts for up to 85% of the 1,125,000 global haemophilia cases

    - PMLiVE

    Sobi receives EC marketing authorisation for Altuvoct in haemophilia A

    The rare bleeding disorder affects approximately one in every 5,000 male births annually

    - PMLiVE

    Sanofi and Sobi’s Altuviiio label updated by FDA with expanded paediatric data in haemophilia A

    The therapy’s weekly dosing has a half-life of up to four times longer than current factor VIII therapies

    - PMLiVE

    Novo Nordisk’s haemophilia A therapy Mim8 shows promise in late-stage study

    Haemophilia A accounts for up to 85% of the 1,125,000 global haemophilia cases

    - PMLiVE

    Sanofi/Sobi’s efanesoctocog alfa recommended by CHMP to treat haemophilia A

    The rare genetic condition reduces production of factor VIII, an essential protein for blood clotting

    Biomarin

    BioMarin announces first patient dosed with haemophilia A gene therapy in Europe

    The therapy was granted conditional marketing authorisation by the EC in August 2022

    - PMLiVE

    FDA approves BioMarin’s Roctavian as first gene therapy for severe haemophilia A

    Approximately 2,500 patients are expected to be eligible to receive the one-time therapy

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links